Solutia Plans to Increase Capacity of Saflex Production in South America

Solutia Inc. (NYSE: SOA) today announced that it is optimizing and expanding its Saflex® polyvinyl butyral (PVB) interlayer manufacturing capacity in South America as part of its strategic plan to continue serving as a leading supplier of PVB technology into the region's architectural and automotive glass markets.

"Solutia's steadfast commitment to the South American market continues to grow. This region, specifically Brazil and Argentina, is a rapidly expanding market for the key automotive and construction industries," said Timothy J. Wessel, president and general manager of Solutia's Advanced Interlayers division.  "We are optimizing our current operations and will be implementing future expansions to better position our customers to seize opportunities in the market."

Saflex is the most trusted name in polyvinyl butyral (PVB) interlayer technology for laminated glazing, delivering outstanding performance and durability backed by reliable and knowledgeable service. Saflex interlayers are found in nearly 40 percent of laminated architectural and automotive glass worldwide, and are also used to encapsulate thin film photovoltaic solar cells, providing outstanding processability and durability. Solutia currently has six manufacturing sites worldwide that produce Saflex PVB interlayers and encapsulants, including a facility in San Jose dos Campos, Brazil.

"As the global economic recovery continues, increased demand for quality interlayer products has followed," said Eric S. Nichols, vice president of business management for Solutia's Advanced Interlayers division. "Solutia will continue to invest in its manufacturing capabilities to meet increased market demand."

Source: http://www.Solutia.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.